PolyPid (PYPD) Non Operating Income (2019 - 2025)
PolyPid (PYPD) posted Non Operating Income of $24000.0 for Q4 2025, down 95.39% sequentially from $521000.0 in Q2 2025, and down 91.61% YoY from $286000.0 in Q4 2024.
PolyPid (PYPD) Non Operating Income (2019 - 2025) Analysis & Trends
PolyPid has reported Non Operating Income for 7 years, with the latest figure at $24000.0 in Q4 2025.
- Quarterly Non Operating Income fell 91.61% year-over-year to $24000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (up 58.68% YoY) and the FY2025 annual result came in at -$685000.0, up 27.97% from the prior year.
- Non Operating Income eased to $24000.0 in Q4 2025 per PYPD's latest filing, from $521000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $678000.0 in Q1 2025 and troughed at -$1.5 million in Q4 2023.
- A 5-year average of $111631.6 and a median of $152000.0 in 2021 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income sank 1610.0% in 2023, then surged 2342.86% in 2024.
- Over 5 years, Non Operating Income stood at $152000.0 in 2021, then slumped by 34.21% to $100000.0 in 2022, then tumbled by 1610.0% to -$1.5 million in 2023, then soared by 118.94% to $286000.0 in 2024, then sank by 91.61% to $24000.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $24000.0, $521000.0, and $678000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24,000.00 |
| Jun 30, 2025 | 521,000.00 |
| Mar 31, 2025 | 678,000.00 |
| Dec 31, 2024 | 286,000.00 |
| Sep 30, 2024 | 354,000.00 |
| Jun 30, 2024 | 171,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Dec 31, 2023 | -1.51 Mn |
| Sep 30, 2023 | 319,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 255,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 437,000.00 |
| Jun 30, 2022 | 281,000.00 |
| Mar 31, 2022 | 78,000.00 |
| Dec 31, 2021 | 152,000.00 |
| Sep 30, 2021 | -129,000.00 |
| Jun 30, 2021 | -153,000.00 |
| Mar 31, 2021 | 110,000.00 |
| Dec 31, 2020 | 339,000.00 |